Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Zentek Ltd V.ZEN

Alternate Symbol(s):  ZTEK

Zentek Ltd. is a Canada-based graphene technology company. The principal business of the Company is to develop opportunities in the graphene and related nano-materials industry based on its intellectual property, patents and unique Albany graphite. The Company is focused on the research, development, and commercialization of graphene-based products. The Company's technology helps filter and... see more

TSXV:ZEN - Post Discussion

Zentek Ltd > Zentek Announces Positive Therapeutic Results achieved by Tr
View:
Post by whytestocks on Jan 30, 2024 1:15pm

Zentek Announces Positive Therapeutic Results achieved by Tr

BREAKING NEWS: $ZTEK Zentek Announces Positive Therapeutic Results achieved by Triera Biosciences for C19HBAGUELPH, ON / ACCESSWIRE / January 30, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN) announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera")has completed testing of its C19HBA aptamer as a potential therapeutic. The SARS-CoV-2 universal aptamer buil...ZTEK - Zentek Announces Positive Therapeutic Results achieved by Triera Biosciences for C19HBA
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities